These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26242994)

  • 21. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
    Retamar P; López-Cerero L; Muniain MA; Pascual Á; Rodríguez-Baño J;
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3402-4. PubMed ID: 23612190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases.
    Babini GS; Yuan M; Hall LM; Livermore DM
    J Antimicrob Chemother; 2003 Mar; 51(3):605-12. PubMed ID: 12615861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS; Moland ES
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.
    Lee J; Oh CE; Choi EH; Lee HJ
    Int J Infect Dis; 2013 Aug; 17(8):e638-43. PubMed ID: 23523562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
    Fujita A; Kimura K; Yokoyama S; Jin W; Wachino J; Yamada K; Suematsu H; Yamagishi Y; Mikamo H; Arakawa Y
    PLoS One; 2015; 10(11):e0142366. PubMed ID: 26539828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.
    Bonfiglio G; Livermore DM
    J Antimicrob Chemother; 1993 Sep; 32(3):431-44. PubMed ID: 8262865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population analysis of Escherichia coli isolates with discordant resistance levels by piperacillin-tazobactam broth microdilution and agar dilution testing.
    Shubert C; Slaughter J; Creely D; van Belkum A; Gayral JP; Dunne WM; Zambardi G; Shortridge D
    Antimicrob Agents Chemother; 2014; 58(3):1779-81. PubMed ID: 24342642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Characterization of Carbapenemase-Nonproducing Clinical Isolates of Escherichia coli (from a Thai University Hospital) with Reduced Carbapenem Susceptibility.
    Nuramrum S; Chanawong A; Lunha K; Lulitanond A; Sangka A; Wilailuckana C; Angkititrakul S; Charoensri N; Wonglakorn L; Chaimanee P; Chetchotisakd P
    Jpn J Infect Dis; 2017 Nov; 70(6):628-634. PubMed ID: 28890516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.
    Monogue ML; Nicolau DP
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7527-7529. PubMed ID: 27799205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Seo YB; Lee J; Kim YK; Lee SS; Lee JA; Kim HY; Uh Y; Kim HS; Song W
    BMC Infect Dis; 2017 Jun; 17(1):404. PubMed ID: 28592240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Importance of Porins and β-Lactamase in Outer Membrane Vesicles on the Hydrolysis of β-Lactam Antibiotics.
    Kim SW; Lee JS; Park SB; Lee AR; Jung JW; Chun JH; Lazarte JMS; Kim J; Seo JS; Kim JH; Song JW; Ha MW; Thompson KD; Lee CR; Jung M; Jung TS
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.
    Tängdén T; Adler M; Cars O; Sandegren L; Löwdin E
    J Antimicrob Chemother; 2013 Jun; 68(6):1319-26. PubMed ID: 23478794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype.
    Sader HS; Hsiung A; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):341-4. PubMed ID: 17141461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.
    Vanscoy B; Mendes RE; Castanheira M; McCauley J; Bhavnani SM; Forrest A; Jones RN; Okusanya OO; Friedrich LV; Steenbergen J; Ambrose PG
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4134-8. PubMed ID: 23774429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests.
    Creely D; Zambardi G; van Belkum A; Dunne WM; Peyret M; Gayral JP; Shortridge D; Shubert C
    Eur J Clin Microbiol Infect Dis; 2013 Aug; 32(8):997-1002. PubMed ID: 23397255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates.
    Cullmann W; Stieglitz M
    Chemotherapy; 1990; 36(5):356-64. PubMed ID: 2170081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S; Marre R
    Infection; 1991; 19(2):106-9. PubMed ID: 1646771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.
    Bergen PJ; Bulitta JB; Sime FB; Lipman J; McGregor MJ; Millen N; Paterson DL; Kirkpatrick CMJ; Roberts JA; Landersdorfer CB
    Diagn Microbiol Infect Dis; 2018 May; 91(1):69-76. PubMed ID: 29395712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D; Yinnon AM; Broide E; Rudensky B
    Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.